安罗替尼治疗肺癌的临床研究进展

Research progress of anlotinib in the treatment of lung cancer

肺癌现已成为我国每年发病及死亡病例数最多的恶性肿瘤。本综述介绍了安罗替尼的作用机制,回顾了单药使用及联合用药的临床实验结果,并结合真实世界回顾性研究分析安罗替尼的疗效及使用的安全性。安罗替尼不论单药还是联合方案均有显著疗效,但受限于现有研究设计的小样本量及病例纳入标准患者的基线PS与临床现实的不完全相符,其结果存在偏差。未来我们可以着力探索安罗替尼联合治疗方案,为患者提供更理想的治疗模式选择。

Lung cancer has become the most common malignant tumor in China.This artical introduces the mechanism of anlotinib,which is known as a new vascular targeting drug,and reviews the clinical experimental results of single and combined use of anlotinib.We also analyse the efficacy and safety of anlotinib used in real world.It is pointed out that both single drug and combination regimen of anlotinib have significant curative effect,but limited by the small sample size of existing research design and the fact that the baseline PS of patients in the case inclusion standard is not completely consistent with the clinical reality and the results are biased.It is suggested that we can focus on the combination regimen of anlotinib to provide patients with more ideal choice of treatment mode in the future.